NCT03091192 2026-04-14
Savolitinib vs. Sunitinib in MET-driven PRCC.
AstraZeneca
Phase 3 Active not recruiting
AstraZeneca
H. Lee Moffitt Cancer Center and Research Institute
University Hospital, Toulouse
VA Office of Research and Development
University of Colorado, Denver
Brigham and Women's Hospital